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Abstract
Background: Previous studies have demonstrated survival benefits for local treatment in solitary metastatic non-
small cell lung cancer (NSCLC).This study aimed to investigate the effect of local surgery for NSCLC with pulmonary
oligometastasis.
Methods: This study included 21 patients of NSCLC with pulmonary oligometastasis between January 2003 and
December 2013, which were divided into two groups, group A (11 cases) for local surgery and group B (10 cases)
for systematic chemotherapy, compared the median survival time (MST) and 5-year survival rate between the two
groups, and analyzed the impact of the pathological types, the TNM and pN stage of primary tumor, the site, and
the mode and number of oligometastatic nodule on group A.
Results: The MST of group A and B were 37 and 11.6 months respectively, 5-year survival rates were 18.2 and
9.1% respectively (p < 0.05). Patients with single nodule, oligo-recurrence, primary tumor of pN0, TNM stage I
or II obtained higher survival rate than those with multiple nodules, sync-oligometastases, pN1-2, stage III or IV in
group A (p < 0.05). There was no significant survival time difference among pathological types of primary tumor
and oligometastatic site (p > 0.05).
Conclusion: Local surgery significantly prolonged the overall survival time and 5-year survival rate of primary
NSCLC with pulmonary oligometastasis.
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Background
Primary lung cancer is one of the most common malig-
nant tumors and is still the leading cause of cancer-
related death in many countries [1, 2]. Approximately
220,000 new cases and 150,000 related deaths are
reported each year in the USA [3]. In China, the incidence
of lung cancer is increasing every year, and mortality is about
0.03%. In clinics, about 80–85% of primary lung cancers are
non-small cell lung cancer (NSCLC). Surgical radical resec-
tion is still the most effective treatment for early stages.
However, 20–50% patients present with metastasis, the
prognosis is poor. The median survival time is about
8–11 months [4]. Approximately 7% of patients with
advanced metastatic NSCLC have a solitary metastasis after
full evaluation [5]. These solitary metastases include sync-
oligometastatic or oligo-recurrent satellite nodules in differ-
ent pulmonary lobes and solitary extrapulmonary metasta-
ses. Hellman and Weichselbaum [6] proposed the term
“oligometastasis,” which was revised by Niibe et al in 2006
[7], to describe this restricted local regional tumor load. It
was a less biologically aggressive tumor stage with a meta-
static number less than five and metastatic site limited to
one single organ, which remain stable over time. Many
previous studies have confirmed the presence of oligometas-
tasis in NSCLC [8–10] and shown the significant effects of
local treatment in improving the overall survival time.
However, most of these studies were focused on extrapul-
monary oligometastasis, rarely on pulmonary oligometastasis.
In the present study, we retrospectively analyzed the
maintained database of patients with pulmonary oligo-
metastasis of NSCLC in our hospital between 2003 and
2013, compared the survival differences between local
surgery and systematic chemotherapy, and investigated
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the effect of local surgery on overall survival time,
median survival time, and 5-year survival rate.
Methods
Patients
We retrospectively identified 21 patients of primary
non-small cell lung cancer with pulmonary oligometas-
tasis in the maintained database (His System) that were
followed up between January 2003 and December 2013
at the third affiliated hospital of Sun Yat-sen University.
The inclusive criteria were as follows: (a) All patients
undergone complete primary tumor resection for
NSCLC; (b) There were one to three pulmonary nodules
in addition of the primary tumor, including sync-
oligometastatic and oligo-recurrent nodules, which were
technically resectable; (c) No distant extrapulmonary
metastases were found. To differentiate pulmonary oli-
gometastasis from second primary lung cancer, we used
the Martini and Melamed criteria [11], which were
modified by Antakli et al [12] and Girard et al [13]. In this
study, “oligometastases” were defined as limited number
(one to five) of pulmonary nodules which could be con-
trolled by local surgery. Sync-oligometastases were defined
as pulmonary nodules that were discovered simultan-
eously or in 6 months after NSCLC were diagnosed, over
6 months was called oligo-recurrence.
This study was approved by the Ethics Committee for
Clinical Research of the third affiliated hospital of Sun
Yat-sen University.
Treatment technique
The 21 inclusive patients were divided into two groups,
the surgery group and the chemotherapy group. Routine
preoperative checkups were done, including laboratory
assessments of the blood cell count, serum chemistry,
the serum tumor markers (CYFRA and NSE), cardiopul-
monary function, and thoracic computed tomography.
The surgical approach included pulmonary wedge resec-
tion and lobectomy, according to the patients’ general
condition. For sync-oligometastases, the time between
primary tumor radical resection and metastatic nodules
resection should be less than 2 months.
Either radiotherapy or chemotherapy was prohibited
before local metastatectomy, with the exception of
adjuvant chemotherapy; after primary radical resection,
oligo-recurrence was detected. All patients in the sur-
gery group accepted adjuvant chemotherapy or dendritic
cell-cytokine-induced killer cell (DC-CIK) immunother-
apy after metastatectomy.
The patients in the chemotherapy group accorded
with the inclusive criteria, however, could not tolerate
operation because of older age, poor physical condition,
or other reasons.
Follow-up
The overall follow-up time was 12 to 72 months, and
the visits were scheduled at 3-month interval for the first
3 years, 6-month interval for the remaining years. At
each visit, physical examination, laboratory assessments
of the blood cell count, serum chemistry and the serum
tumor markers (NSE and CYFRA), and chest X-rays
were performed. In addition, thoracic CT and bone scans
were done when clinically indicated.
Statistical analyses
Statistical analysis was performed using SPSS15.1 (SPSS
Inc, Chicago, IL). The Kaplan-Meier test was used to
analyze overall survival and 5-year survival rate, which
were calculated from the date of primary radical resec-
tion of NSCLC to death or the last follow-up for patients
who were still alive. Univariate analysis between groups
was done by the log-rank test. A two-sided p value of
<0.05 was considered to be statistically significant.
Results
Patient characteristics
The surgery group included eleven patients (Table 1
shows patients’ characteristics). The media age was
56.4 years, ranged from 41 to 75 years, including six
males and five females. The diameter of primary tumor
was 1.5–7.1 cm, and the number of metastatic nodules
was 1–3. Ipsilateral pulmonary oligometastases were
found in four patients, and contralateral in other seven
patients. Sync-oligometastases and oligo-recurrence
were found in three and eight patients, respectively.
Pulmonary wedge resection was performed in ten
cases, six of which only had one metastatic nodule.
Lobectomy was done only in one patient, with three
oligometastatic nodules locating in the same lobe. The
average time interval between sync-oligometastatic
resection and primary tumor radical resection was
41.4 days. No serious postoperative complications were
found among patients. The postoperative pathological
diagnosis showed seven cases that were adenocarcinoma,
three squamous cell carcinoma, and one large cell
carcinoma.
Postoperative adjuvant chemotherapy was done among
the eleven patients, eight of whom finished four courses,
three accepted DC-CIK immunotherapy after one or
two courses, because of serious chemotherapy blood
toxicity. The chemotherapy group included ten patients,
with the median age of 60 years, six of which were males
four were females.
Survival
All patients were followed up for 15–72 months; the
median follow-up time was 37.5 months. In the local
surgery group, four patients (36.4%) were alive with
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stable disease at the time of the analysis, the remaining
died of specific lung cancer progression during the
follow-up period. The overall survival time (OS) ranged
from 19 to 71 months for the surgery group, and median
survival time (MST) was 37 months. The OS for
chemotherapy group was 9–61 months, while MST was
11.6 months. The overall 5-year survival rate for the
surgery and chemotherapy group was 18.2 and 9.1%
respectively. The OS and 5-year survival rate of the sur-
gery group were significantly higher than the chemother-
apy group (p < 0.05). Figure 1 shows the Kaplan-Meier
curve for the OS of the two groups.
Table 2 shows the univariate analysis of the poten-
tial factors for overall survival of the surgery group.
The sex, age, the primary tumor site and oligometa-
static site (ipsilateral or contralateral), and histological
subtypes showed no statistical significant differences
to survival (p > 0.05). However, in lower pN and
Fig. 1 The Kaplan-Meier curve of overall survival time for group A
and B
Table 2 Univariate analysis of predictive factors for OS of the
surgical group (n = 11)
Predictive factors Patients 5-year OS (%) Log-rank p value
Gender
Male 6 16.7
Female 5 20.0 0.956
Age (years)
>50 7 14.3
≤50 4 25.0 0.176
Histological subtypes of primary tumor
Adenocarcinoma 8 12.5
Non-adenocarcinoma 3 33.3 0.855
Oligometastatic site
Ipsilateral lung 4 50.0
Contralateral lung 7 0.00 0.104
Oligometastatic mode
Sync-oligometastasis 3 0.00
Oligo-recurrence 8 25.0 0.012
Number of oligometastatic nodules
One 6 33.3
Two or Three 5 0.00 0.040
pN of primary tumor
N0 4 50.0
N1 or N2 7 0.00 0.038
TNM stage of primary tumor
I or II 7 28.6
III or IV 4 0.00 0.0004
Italicized figures represent statistically significant difference
Table 1 Clinical characteristics and survival for the surgery group (n = 11)
Patients Sex Age
(years)
Size (cm) pN TNM stage Histology Oligometastatic Surgical
approach
Outcome Survival
of primary tumor Mode Number Site (Months)
1 M 61 1.6 0 IA Ad R 1 IL PWR Dead 69
2 F 45 1.5 0 IA Sq R 1 IL PWR Alive 71
3 F 71 2.8 2 IV Ad S 2 CL PWR Dead 21
4 M 44 3.2 1 IIA Ad R 2 CL PWR Alive 37
5 F 59 5.4 1 IV Ad S 2 IL PWR Dead 29
6 M 63 1.9 1 IIA Ad R 1 IL PWR Alive 42
7 F 52 2.3 0 IA Ad R 1 CL PWR Dead 51
8 M 75 7.1 2 IIIA Lc R 2 CL PWR Dead 15
9 M 47 2.2 0 IA Ad R 1 CL PWR Alive 41
10 F 41 6.4 1 IIB Ad R 3 CL LO Dead 17
11 M 62 4.5 2 IV Sq S 1 CL PWR Dead 19
Abbreviations: M male, F female, Ad adenocarcinoma, Sq squamous cell carcinoma, Lc large cell carcinoma, R oligo-recurrence, S sync-oligometastasis, IL ipsilateral
lung, CL contralateral lung, PWR pulmonary wedge resection, LO lobectomy
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TNM stage, single and oligo-recurrence were associ-
ated with better survival (p < 0.05).
Discussion
Although local treatment in metastatic non-small cell
lung cancer is still controversial, many previous research
[10, 14–16] have reported parts of selective patients that
benefited from it, but radical resection of the primary
tumor was necessary. Many studies [6, 17–19] also dem-
onstrated local resection of the metastatic lesion that
improved the survival time. The 5-year survival rate
reached 15% after surgical resection of the solitary brain
metastasis, and 25% for solitary adrenal metastasis after
adrenalectomy. Tokujiro Yano et al [20] reported that
the median FPS and overall survival time were
12.1 months and 13.5 months after local treatment for
sync-oligometastasis of NSCLC, but only a small part of
patients benefited. However, patients with oligo-recurrent
effectively benefited, whose median FPS reached
20 months. Our present study was consistent with their
viewpoint. The OS for oligo-recurrence was 41.5 months
compaired with 21 months for sync-oligometastasis,
which was significantly different (p = 0.012).
Given the favorable results of local treatments for
oligometastatic disease, new treatment strategies based
on new diagnostic criteria and aggressive treatment
options must be considered. The study from Postmus et
al [21] shown 5-year survival rate that was about 28%
for pulmonary oligometastatic satellite nodules resec-
tion, which was much more favorable than the patients
who received palliative systemic chemotherapy. Kozower
et al [18] reported 5-year survival rate that was 13% after
resection of ipsilateral pulmonary oligometastasis. Voltolini
et al [22] analyzed long-term survival rates after complete
surgical resection of synchronous multiple lung cancers,
both ipsilaterally (n = 27) and contralaterally (n = 28), the
5-year survival rate was not significantly different between
the two groups, reported to be 27 and 43% respectively.
They further demonstrated lymph node metastases which
were important parameters influencing prognosis. In a
study of 66 patients of synchronous bilateral pulmonary
oligometastasis, OS and 5-year survival rate were re-
ported to be 25.4 months and 38% respectively after
simultaneously resection of bilateral metastastic nodules
[23]. The recent study from Endo et al [24] concluded that
Clinical T1-2N0-1 NSCLC with oligometastatic lesion was
a good candidate for surgical resection, 5-year survival rate
of about 40% can be expected. They also demon-
strated that it was important that the indication was
limited to intrathoracic clinical stage I or II. Approxi-
mately 60% of such patients could undergo complete
resection of both the primary NSCLC and a true metasta-
sis, and benefited.
Despite the survival time that varies from each other,
we conclude from the above literatures that local treat-
ment does improve parts of selective patients with oligo-
metastatic NSCLC and make them benefit. This is
consistent with our study. The median survival time and
5-year survival rate in the surgical group were 37 months
and 18.2%, respectively, which were significantly better
than systematic chemotherapy. We also conclude from
our study that patients with lower pN and TNM stage,
single and oligo-recurrence were associated with better
survival. These factors can be regarded as prognostic
factors.
Mortality rates were reported between 0 and 2.5% in
pulmonary metastasectomy for extrapulmonary primary
tumors [25]. Thus, it can be expected that a sequential
approach for NSCLC and oligometastatic disease can be
done with a comparable low mortality rate. However,
local oligometastasectomy after radical resection of
NSCLC could be done only when patients can tolerate
operation after total evaluation; otherwise, chemotherapy
is the only choice. In this study, ten exclusive patients
underwent chemotherapy because of older age, poor
physical condition, or other reasons, with MST of
11.6 months, and died of tumor progression. To our
experience, the preferred surgical approach is pulmonary
wedge resection and segmentectomy; lobectomy is not
recommended because of relatively higher operation risk
and greater trauma. Only one patient underwent lobec-
tomy in our study, postoperative recovery time is
relatively longer than that in primary tumor radical
resection. For sync-oligometastases, segmentectomy or
wedge resection on the contrary side should be per-
formed first if the primary tumor requires a lobectomy
or bilobectomy.
Conclusions
The study of local surgery in non-small cell lung cancer
with pulmonary oligometastasis is rare. For these patients,
our present study have demonstrated that the median
survival time and overall 5-year survival rate reached
37 months and 18.2% respectively after pulmonary
oligometastasectomy. NSCLC patients with pulmonary
oligometastasis could benefit from local surgery.
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